MED3000 has been granted marketing authorisation in a growing number of countries across the world which now include Mexico, six countries in the Middle East (including Saudi Arabia) and Australia.
Futura has signed commercial deals across the world covering Europe, the USA, Central and South America, the Middle East and South Korea with the first launch outside of Europe, in the United Arab Emirates, having commenced at the beginning of Q4, 2023 with further launches expected over the coming months:
August 2021: m8 Pharmaceuticals to commercialise MED3000 in Brazil and Mexico, which was expanded in November 2023 to a further fourteen countries covering the Central and South American region.
September 2021: Labatec Pharma to commercialise MED3000 in the Gulf and Middle East Region.
March 2022: A. Menarini Korea Limited for the exclusive rights to MED3000 in South Korea.
May 2022: Cooper Consumer Health to commercialise MED3000 throughout the European Economic Area, United Kingdom and Switzerland.
In 2023, Futura signed or expanded the following commercial deals:
July 2023: Haleon to exclusively commercialise MED3000 in the USA.
November 2023: Futura expands partnership with M8 Pharmaceuticals.